First in patient study of anti-GM-CSF monoclonal antibody (MOR103) in active rheumatoid arthritis: Results of a phase 1b/2a randomized, double-blind, placebo-controlled trial.

F. Behrens; Mikkel Østergaard; R. Stoilov; P. Wiland; T.W. Huizinga; V.Y. Berenfus; P.-P. Tak; S. Vladeva; J. Rech; A. Rubbert-Roth; M. Korkosz; D. Rekalov; I.A. Zupanets; B.J. Ejbjerg; J. Geiseler; J. Fresenius; R.P. Korolkiewicz; A.J. Schottelius; H. Burkhardt

doi:10.1002/art.37771

First in patient study of anti-GM-CSF monoclonal antibody (MOR103) in active rheumatoid arthritis: Results of a phase 1b/2a randomized, double-blind, placebo-controlled trial.

F. Behrens, Mikkel Østergaard, R. Stoilov, P. Wiland, T.W. Huizinga, V.Y. Berenfus, P.-P. Tak, S. Vladeva, J. Rech, A. Rubbert-Roth, M. Korkosz, D. Rekalov, I.A. Zupanets, B.J. Ejbjerg, J. Geiseler, J. Fresenius, R.P. Korolkiewicz, A.J. Schottelius, H. Burkhardt

Original language	English
Journal	Arthritis & Rheumatism
ISSN	0004-3591
DOIs	https://doi.org/10.1002/art.37771
Publication status	Published - 2012

Access to Document

10.1002/art.37771

Cite this

Behrens, F., Østergaard, M., Stoilov, R., Wiland, P., Huizinga, T. W., Berenfus, V. Y., Tak, P-P., Vladeva, S., Rech, J., Rubbert-Roth, A., Korkosz, M., Rekalov, D., Zupanets, I. A., Ejbjerg, B. J., Geiseler, J., Fresenius, J., Korolkiewicz, R. P., Schottelius, A. J., & Burkhardt, H. (2012). First in patient study of anti-GM-CSF monoclonal antibody (MOR103) in active rheumatoid arthritis: Results of a phase 1b/2a randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism. https://doi.org/10.1002/art.37771

Behrens, F, Østergaard, M, Stoilov, R, Wiland, P, Huizinga, TW, Berenfus, VY, Tak, P-P, Vladeva, S, Rech, J, Rubbert-Roth, A, Korkosz, M, Rekalov, D, Zupanets, IA, Ejbjerg, BJ, Geiseler, J, Fresenius, J, Korolkiewicz, RP, Schottelius, AJ & Burkhardt, H 2012, 'First in patient study of anti-GM-CSF monoclonal antibody (MOR103) in active rheumatoid arthritis: Results of a phase 1b/2a randomized, double-blind, placebo-controlled trial.', Arthritis & Rheumatism. https://doi.org/10.1002/art.37771

@article{7e66c136667b43a0ba180d18762da816,

title = "First in patient study of anti-GM-CSF monoclonal antibody (MOR103) in active rheumatoid arthritis: Results of a phase 1b/2a randomized, double-blind, placebo-controlled trial.",

author = "F. Behrens and Mikkel {\O}stergaard and R. Stoilov and P. Wiland and T.W. Huizinga and V.Y. Berenfus and P.-P. Tak and S. Vladeva and J. Rech and A. Rubbert-Roth and M. Korkosz and D. Rekalov and I.A. Zupanets and B.J. Ejbjerg and J. Geiseler and J. Fresenius and R.P. Korolkiewicz and A.J. Schottelius and H. Burkhardt",

note = "Late-breaking abstract L11",

year = "2012",

doi = "10.1002/art.37771",

language = "English",

journal = "Arthritis & Rheumatology",

issn = "2326-5205",

publisher = "Wiley",

}

TY - ABST

T1 - First in patient study of anti-GM-CSF monoclonal antibody (MOR103) in active rheumatoid arthritis: Results of a phase 1b/2a randomized, double-blind, placebo-controlled trial.

AU - Behrens, F.

AU - Østergaard, Mikkel

AU - Stoilov, R.

AU - Wiland, P.

AU - Huizinga, T.W.

AU - Berenfus, V.Y.

AU - Tak, P.-P.

AU - Vladeva, S.

AU - Rech, J.

AU - Rubbert-Roth, A.

AU - Korkosz, M.

AU - Rekalov, D.

AU - Zupanets, I.A.

AU - Ejbjerg, B.J.

AU - Geiseler, J.

AU - Fresenius, J.

AU - Korolkiewicz, R.P.

AU - Schottelius, A.J.

AU - Burkhardt, H.

N1 - Late-breaking abstract L11

PY - 2012

Y1 - 2012

U2 - 10.1002/art.37771

DO - 10.1002/art.37771

M3 - Conference abstract in journal

SN - 2326-5205

JO - Arthritis & Rheumatology

JF - Arthritis & Rheumatology

ER -